Literature DB >> 12925960

Smoking, DNA repair capacity and risk of nonsmall cell lung cancer.

Hongbing Shen1, Margaret R Spitz, Yawei Qiao, Zhaozheng Guo, Li-E Wang, Carol H Bosken, Christopher I Amos, Qingyi Wei.   

Abstract

Tobacco-related carcinogens cause a variety of DNA damage that is repaired by different enzymatic pathways, suggesting that DNA repair plays an important role in tobacco-induced carcinogenesis. In a large hospital-based case-control study, we investigated DNA repair capacity (DRC) as a biomarker for susceptibility to nonsmall cell lung cancer (NSCLC) and evaluated the possible interaction between DRC and tobacco smoke in 467 newly diagnosed NSCLC patients and 488 cancer-free controls. We measured DRC in cultured peripheral lymphocytes using the host-cell reactivation assay with a reporter gene damaged by an activated tobacco carcinogen, benzo[a]pyrene diol epoxide. The results showed that current smokers exhibited the highest DRCs as compared to former and nonsmokers both among patients and control subjects. There were no differences of DRC among 3 different histopathologic types of NSCLC. Logistic regression analysis revealed that suboptimal DRC and pack-years smoked were independent predictors of NSCLC risk. The overall 15.5% reduction in DRC observed in the cases (7.84%) compared to the controls (9.28%) (p<0.001) was associated with an approximately 2-fold increased risk of NSCLC (adjusted odds ratio (OR) = 1.85, 95% confidence interval (CI) 1.42-2.42). There was a significant dose-response association between decreased DRC and increased risk of lung cancer. Furthermore, we observed a nonstatistically significant additive but not multiplicative interaction between DRC and pack-years smoked on lung cancer risk, particularly in the histopathologic types of NSCLC other than adenocarcinoma. The results suggest that suboptimal DRC is associated with increased risk of NSCLC and DRC may modulate the risk of lung cancer associated with smoking but the latter needs to be verified in larger studies. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925960     DOI: 10.1002/ijc.11346

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Bulky DNA adducts in white blood cells: a pooled analysis of 3,600 subjects.

Authors:  Fulvio Ricceri; Roger W Godschalk; Marco Peluso; David H Phillips; Antonio Agudo; Panagiotis Georgiadis; Steffen Loft; Anne Tjonneland; Ole Raaschou-Nielsen; Domenico Palli; Frederica Perera; Roel Vermeulen; Emanuela Taioli; Radim J Sram; Armelle Munnia; Fabio Rosa; Alessandra Allione; Giuseppe Matullo; Paolo Vineis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-04       Impact factor: 4.254

2.  Efficiency of nonhomologous DNA end joining varies among somatic tissues, despite similarity in mechanism.

Authors:  Sheetal Sharma; Bibha Choudhary; Sathees C Raghavan
Journal:  Cell Mol Life Sci       Date:  2010-08-03       Impact factor: 9.261

3.  Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.

Authors:  Neil D Gross; Jay O Boyle; Jason D Morrow; Myles K Williams; Chaya S Moskowitz; Kotha Subbaramaiah; Andrew J Dannenberg; Anna J Duffield-Lillico
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

4.  DNA damage phenotype and prostate cancer risk.

Authors:  O Kosti; L Goldman; D T Saha; R A Orden; A J Pollock; H L Madej; A W Hsing; L W Chu; J H Lynch; R Goldman
Journal:  Mutat Res       Date:  2010-11-21       Impact factor: 2.433

5.  Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation.

Authors:  Shuguang Leng; Christine A Stidley; Randy Willink; Amanda Bernauer; Kieu Do; Maria A Picchi; Xin Sheng; Melissa A Frasco; David Van Den Berg; Frank D Gilliland; Christopher Zima; Richard E Crowell; Steven A Belinsky
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

6.  Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.

Authors:  Mi-Sun Lee; Chen-yu Liu; Li Su; David C Christiani
Journal:  Lung Cancer       Date:  2015-05-11       Impact factor: 5.705

7.  Comprehensive assessment of the association between XPD rs13181 polymorphism and lung cancer risk.

Authors:  Hai-Ying Wu; Ling-Yu Ding
Journal:  Tumour Biol       Date:  2014-05-21

8.  DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.

Authors:  Ivo Teneng; Maria A Picchi; Shuguang Leng; Christopher P Dagucon; Suresh Ramalingam; Carmen S Tellez; Steven A Belinsky
Journal:  DNA Repair (Amst)       Date:  2019-04-27

9.  Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Wu Wei; Xiao-Feng He; Jiang-Bo Qin; Jiao Su; Shao-Xia Li; Yi Liu; Ying Zhang; Wei Wang
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

10.  Xeroderma Pigmentosum Group C Deficiency Alters Cigarette Smoke DNA Damage Cell Fate and Accelerates Emphysema Development.

Authors:  Catherine R Sears; Huaxin Zhou; Matthew J Justice; Amanda J Fisher; Jacob Saliba; Isaac Lamb; Jessica Wicker; Kelly S Schweitzer; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2018-03       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.